GlassScriptPhysician profile
Amanda H Descalzo
NPI 1508110255
$4,245.88
in general payments reported to CMS, 2019-2025
23 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $412 · 2023: $999 · 2024: $1,346 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227 · Travel and Lodging: $205 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.44 |
| Travel and Lodging | $205.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.24 | 2021-2025 | |
| Enterra Medical, INC. | $508.13 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.80 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $458.97 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $394.94 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $241.75 | 2024-2025 | Omvoh, Zepbound |
| Genzyme Corporation | $217.83 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $176.41 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $134.54 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.27 | 2023-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $109.13 | 2022-2024 | Linzess |
| Ardelyx, INC. | $97.39 | 2024-2025 | Ibsrela |
| Pfizer INC. | $97.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $53.36 | 2024 | Andexxa |
| Madrigal Pharmaceuticals | $40.89 | 2025 | Rezdiffra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Henry Schein, INC. | $33.52 | 2024 | |
| Celgene Corporation | $31.00 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $27.94 | 2025 | Sucraid |
| Csl Behring | $25.73 | 2022 | |
| Merck Sharp & Dohme LLC | $20.88 | 2021 | |
| Aimmune Therapeutics, INC. | $15.60 | 2024 | |
| Evoke Pharma, INC. | $14.95 | 2025 | |
| Vivus LLC | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Descalzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.